Transgene advances lead cancer vaccine TG4050

27 March 2025

French biotech company Transgene (Euronext Paris: TNG) has reported its 2024 financial results and provided updates on its cancer immunotherapy pipeline.

The company highlighted significant progress in developing TG4050, an individualized therapeutic cancer vaccine derived from its myvac platform.

In 2024, Transgene achieved a clinical proof of principle for TG4050. Early results from the Phase I part of the Phase I/II trial in head and neck cancer patients showed that all individuals treated with TG4050 remained disease-free after a median follow-up of 24.1 months.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK